Radicava™ (Edaravone) was approved the Food and Drug Administration (FDA) as a new
treatment for amyotrophic lateral sclerosis (ALS). Edaravone is a synthetic antioxidant that specifically
targets oxidative damage interacting with lipid radicals in the cell. In ALS disease the multiple cell
types are involved in devastating loss of motor neurons. Mutations and biochemical changes in various
cell types jointly contribute to motor neuron death, disease onset, and disease progression. The
overall mechanism of neurodegeneration in ALS is still not completely understood. Dying motor neurons
have been reported to exhibit features of apoptosis. However, non-apoptotic features of dying
motor neurons have also been reported such as ferroptosis. The role of Edaravone in the prevention of
ferroptosis in parallel with other therapeutic approaches to ALS therapy is discussed.
Keywords: Edaravone, amyotrophic lateral sclerosis (ALS), ferroptosis, therapy, neurons, neurodegeneration.
Rights & PermissionsPrintExport